SCHEMBL3886808

SCHEMBL3886808

O=C(Nc1c(Cl)cccc1Cl)C(=O)c1c(-c2cccnc2)cc2ccccn12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
THRB P10828 1/20 0.50
MAPT P10636 6/20 0.47
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 3/20 0.46
PDE4A P27815 6/20 0.41
PDE4B Q07343 6/20 0.41
PDE4C Q08493 6/20 0.41
PDE4D Q08499 6/20 0.41
IRAK4 Q9NWZ3 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
MEN1 O00255 2/20 0.39
PKM P14618 1/20 0.39
ADORA2B P29275 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644594 0.90 ALDH1A1 (0.54) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL3885921 0.89 L3MBTL1 (0.62) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1645621 0.85 L3MBTL1 (0.50) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1645449 0.85 KMT2A (0.51) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1646858 0.85 ALDH1A1 (0.49) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL3888278 0.82 THRB (0.59) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1645261 0.82 THRB (0.58) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1644590 0.82 SMN1; SMN2 (0.55) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1646445 0.81 THRB (0.53) L3MBTL1THRBMAPTHTTSMN1; SMN2
SCHEMBL1647279 0.81 L3MBTL1 (0.50) L3MBTL1THRBMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 L3MBTL1 3386/4885THRB 2955/4885MAPT 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.